Filtered By:
Source: The American Journal of Cardiology
Procedure: Heart Valve Surgery
This page shows you your search results in order of date.
Order by Relevance | Date
Total 34 results found since Jan 2013.
Antithrombotic Medication and Major Complications After Mechanical Aortic Valve Replacement
Patients with mechanical aortic valve replacement (AVR) require lifelong vitamin K antagonist (VKA) therapy for stroke and systemic embolism prevention. However, VKA treatment predisposes patients to various types of bleeding. In the present study, we sought to assess the success of antithrombotic therapy and the occurrence and timing of strokes and bleeding events after mechanical AVR. A total of 308 patients who underwent isolated mechanical AVR were included in the study, and follow-up data were completed for 306 patients (99.4%).
Source: The American Journal of Cardiology - August 5, 2023 Category: Cardiology Authors: Rikhard Bj örn, Joonas Lehto, Markus Malmberg, Vesa Anttila, K.E. Juhani Airaksinen, Jarmo Gunn, Tuomas Kiviniemi Source Type: research
Transcatheter Aortic Valve Implantation: Transvascular Is the Way to Go!
There is no doubt that transcatheter aortic valve implantation (TAVI) has been widely accepted by the whole medical community dedicated to the heart care of patients with aortic valve stenosis. Increasing clinical experience and constant refinement of devices and procedural techniques have resulted in improved outcomes, especially since the generalized use of the transfemoral approach for TAVI.1 So far, only transfemoral TAVI has been associated with a significant reduction of mortality or disabling stroke in patients at intermediate risk, compared with surgical aortic valve replacement (AVR).
Source: The American Journal of Cardiology - July 1, 2023 Category: Cardiology Authors: Thierry Bov é Tags: Editorial Source Type: research
Meta-Analysis of Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement
Transcatheter aortic valve replacement (TAVR) has emerged as an effective therapy for patients with severe aortic stenosis, irrespective of surgical risks.1 Stroke due to cerebral embolization of debris is a devastating periprocedural complication of TAVR and is associated with poor outcomes. The risk of stroke could be decreased by capturing the debris using cerebral embolic protection (CEP) devices.2 An analysis of the TVT (Transcatheter Valve Therapy) Registry showed that CEPs were used in 28% of centers and 13% of all procedures.
Source: The American Journal of Cardiology - February 27, 2023 Category: Cardiology Authors: Ahmad Al-Abdouh, Mohammed Mhanna, Ahmad Jabri, Taha Ahmed, Ahmed M. Altibi, Fares Ghanem, Laith Alhuneafat, Ayman Albadawi, Mahmoud Barbarawi, Nakeya Dewaswala, Huzefa Bhopalwala, Amartya Kundu, Islam Y. Elgendy Source Type: research
Cerebral Embolic Protection in Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Clinical Trials
Transcatheter aortic valve replacement (TAVR) has become a mainstay treatment option for most patients with severe symptomatic aortic stenosis. Although the majority of TAVR-related complications have decreased overtime, stroke rates remained relatively unchanged.1,2 Hence, numerous efforts have been devoted to developing effective strategies to mitigate the risk of post-TAVR strokes. We performed an updated meta-analysis to assess the efficacy and safety of cerebral embolic protection (CEP) during TAVR.
Source: The American Journal of Cardiology - November 14, 2022 Category: Cardiology Authors: Abdullah Al-Abcha, Yehia Saleh, Muhannad Abbasi, Edward El-Am, Mohamad Alkhouli Source Type: research
Feasibility of Sentinel Cerebral Embolic Protection Device Deployment During Transfemoral Transcatheter Aortic Valve Replacement
Cerebral embolic protection has emerged as a preventive measure for procedural stroke in transcatheter aortic valve replacement (TAVR).1 The Sentinel System (Boston Scientific Corp. Boston, Massachusetts), a 2-filter debris-capturing system, has been the only commercially available protection device in the United States since its approval by the Food and Drug Administration in 2017. In the Sentinel trial, the largest randomized trial (n = 363) so far, the device was successfully deployed in 94.7% of patients.
Source: The American Journal of Cardiology - October 1, 2022 Category: Cardiology Authors: Toshiaki Isogai, Husitha Reddy Vanguru, Amar Krishnaswamy, Ankit Agrawal, Nikolaos Spilias, Shashank Shekhar, Anas M. Saad, Beni Rai Verma, Rishi Puri, Grant W. Reed, Zoran B. Popovi ć, Shinya Unai, James J. Yun, Ken Uchino, Samir R. Kapadia Source Type: research
Transcatheter and Surgical Aortic Valve Implantation in Children, Adolescents, and Young Adults With Congenital Heart Disease
Transcatheter aortic valve implantation (TAVI) is common in adults but rare in children and adolescents. Since 2014, our institution has incorporated a transcatheter approach as an option for aortic valve replacement in this population. The purpose of this study was to compare short-term outcomes of TAVI with surgical aortic valve replacement (SAVR). This single-center, retrospective study included patients aged 10 to 21 years who had a native SAVR or TAVI between January 2010 to April 2020. Comparative analysis of baseline characteristics and a composite outcome (stroke within 6 months, readmission within 30 days, death) ...
Source: The American Journal of Cardiology - June 9, 2022 Category: Cardiology Authors: Dwight M. Robertson, Dana M. Boucek, Mary Hunt Martin, Robert G. Gray, Eric R. Griffiths, Aaron W. Eckhauser, Zhining Ou, Linda M. Lambert, Richard V. Williams, S. Adil Husain Source Type: research
Meta-Analysis of 5-Year Risk of All-Cause Death or Stroke After Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement
Transcatheter aortic valve implantation (TAVI) is an established alternative to surgical aortic valve replacement (SAVR) for patients with severe symptomatic aortic stenosis.1,2 Its indication has expanded from high-risk to include a low surgical risk younger population. Although the short-term results of TAVI and SAVR in patients with intermediate or high surgical risk are similar,1,2 outcomes beyond short-term periods remain unclear. Recently, the results of 5-year follow-up of the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial has been reported, which showed a similar rate of the compos...
Source: The American Journal of Cardiology - January 3, 2022 Category: Cardiology Authors: Yujiro Yokoyama, Toshiki Kuno, Tomo Ando, Tadahisa Sugiura, Azeem Latib Source Type: research
Risk of Ischemic Stroke in Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients With Prior Stroke
It has not been well studied whether transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) have lower risk of ischemic stroke (IS) in those with prior history of IS. From the Nationwide Readmission Database from October 2015 to November 2017, TAVI and SAVR above age 50 were identified with the International Classification of Diseases, Tenth Revision, Clinical Modification/Procedure Coding System codes. Transapical TAVI and SAVR with concomitant bypass, mitral, or tricuspid surgery were excluded.
Source: The American Journal of Cardiology - August 6, 2021 Category: Cardiology Authors: Tomo Ando, Said Ashraf, Alexandros Briasoulis, Hisato Takagi, Cindy L. Grines, Aaqib H. Malik Tags: Valvular Heart Disease Source Type: research
Impact of Ventricular Stroke Work Indices on Mortality in Heart Failure Patients after Percutaneous Mitral Valve Repair
Transcatheter mitral valve repair (TMVR) using the MitraClip system (Abbott Vascular, Abbott Park, Illinois) has emerged as an effective treatment option for surgical high-risk patients with severe functional mitral regurgitation (MR) and chronic heart failure (CHF)1-9. However, several predictors of worse prognosis in patients treated by TMVR have been identified, e.g. high levels of NT-proBNP, New York Heart Association (NYHA) functional class IV prior to TMVR and a severely impaired left and right heart function5,8,10-13.
Source: The American Journal of Cardiology - February 25, 2021 Category: Cardiology Authors: Rico Osteresch, Kathrin Diehl, Patrick Dierks, Johannes Schmucker, Azza Ben Ammar, Andreas Fach, Harald Langer, Ingo Eitel, Rainer Hambrecht, Harm Wienbergen Source Type: research
Meta-Analysis of Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement
Transcatheter aortic valve replacement (TAVR) has evolved as an important treatment option for patients with severe symptomatic aortic stenosis. Despite advancements with device design, procedural techniques, and improved operator experience, stroke rates after TAVR have not declined( ∼2.5%), as per the recent data from the national cardiovascular database registry.1 Embolic protection devices (EPDs) were introduced to prevent embolization of thrombotic or calcified debris during TAVR. However, randomized controlled trials (RCTs) that investigated the efficacy and safety of the se devices have been underpowered for clinical endpoints.
Source: The American Journal of Cardiology - October 23, 2020 Category: Cardiology Authors: Salik Nazir, Fnu Zafrullah, Hafeez U.H. Virk, Charnjeet Singh Sandhu, Muhammad Ameen, Keerat Rai Ahuja Source Type: research
Outcomes of Transcatheter Aortic Valve Replacement with Percutaneous Coronary Intervention versus Surgical Aortic Valve Replacement with Coronary Artery Bypass Grafting
We aimed to compare the outcomes of combined surgical aortic valve replacement (SAVR) with coronary artery bypass grafting (CABG) to concurrent transcatheter aortic valve replacement (TAVR) with percutaneous coronary intervention (PCI) in a large U.S. population sample. The National Inpatient Sample (NIS) was queried for all patients diagnosed with aortic valve stenosis who underwent SAVR with CABG or TAVR with PCI during the years 2016-2017. Study outcomes included all-cause in-hospital mortality, acute stroke, pacemaker insertion, vascular complications, major bleeding, acute kidney injury, sepsis, non-home discharge, le...
Source: The American Journal of Cardiology - September 25, 2020 Category: Cardiology Authors: Ashraf Abugroun, Mohammed Osman, Saria Awadalla, Lloyd Klein Source Type: research
Propensity-Matched Comparison of Evolut-R Transcatheter Aortic Valve Implantation With Surgery in Intermediate-Risk Patients (from the SURTAVI Trial)
The Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial demonstrated the noninferiority of transcatheter aortic valve implantation (TAVI) using a self-expanding bioprosthesis to surgical aortic valve replacement (SAVR) for the primary end point of all-cause mortality or disabling stroke at 2 years in patients with severe, symptomatic aortic stenosis at intermediate risk for surgery.1 The majority of TAVI patients in the SURTAVI trial (84%) received the first generation CoreValve bioprosthesis (Medtronic, Minneapolis, Minnesota).
Source: The American Journal of Cardiology - June 28, 2020 Category: Cardiology Authors: Steven J. Yakubov, Nicolas M. Van Mieghem, Michael J. Reardon, Patrick W. Serruys, Hemal Gada, Mubashir Mumtaz, G. Michael Deeb, Susheel Kodali, Isaac George, Stephan Windecker, Neal Kleiman, Stanley J. Chetcuti, Carlos Sanchez, Harold L. Dauerman, Shuzhe Source Type: research
Propensity-Matched Comparison of Evolut R Transcatheter Aortic Valve Implantation with Surgery in Intermediate-Risk Patients (From the SURTAVI Trial)
The Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial demonstrated the noninferiority of transcatheter aortic valve implantation (TAVI) using a self-expanding bioprosthesis to surgical aortic valve replacement (SAVR) for the primary endpoint of all-cause mortality or disabling stroke at 2 years in patients with severe, symptomatic aortic stenosis at intermediate risk for surgery.1 The majority of TAVI patients in the SURTAVI trial (84%) received the first generation CoreValve bioprosthesis (Medtronic, Minneapolis, MN).
Source: The American Journal of Cardiology - June 28, 2020 Category: Cardiology Authors: Steven J. Yakubov, Nicolas M. Van Mieghem, Michael J. Reardon, Patrick W. Serruys, Hemal Gada, Mubashir Mumtaz, G. Michael Deeb, Susheel Kodali, Isaac George, Stephan Windecker, Neal Kleiman, Stanley J. Chetcuti, Carlos Sanchez, Harold L. Dauerman, Shuzhe Source Type: research
Valve-in-Valve Transcatheter Implantation versus Redo Surgical Aortic Valve Replacement
Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) for a failing prosthesis is an appealing alternative to redo surgical AVR. We utilized data from the US National Inpatient Sample for the period 2012-2016 to identify hospitalizations for either ViV-TAVI or redo-SAVR. The primary outcomes of interest were in-hospital adverse events composite outcome (comprising of mortality, myocardial infarction, stroke, or acute kidney injury) and all-cause mortality. We used propensity score matching to adjust for the baseline differences between ViV-TAVI and redo-SAVR cohorts.
Source: The American Journal of Cardiology - February 7, 2020 Category: Cardiology Authors: Aaqib H. Malik, Srikanth Yandrapalli, Syed Zaid, Suchith S Shetty, Wilbert S. Aronow, Hasan Ahmad, Gilbert H.L. Tang Source Type: research
Meta-Analysis Comparing Results of Transcatheter versus Surgical Aortic-Valve Replacement in Patients with Severe Aortic Stenosis
Transcatheter aortic-valve replacement (TAVR) has emerged as a promising strategy for treating patients with severe aortic stenosis. We aimed to compare TAVR with surgical aortic-valve replacement (SAVR) and determine the performance of TAVR over time and within several subgroups. We included 8 randomized trials comparing TAVR vs. SAVR. Compared with SAVR, TAVR was associated with a lower rate of all-cause mortality or disabling stroke at 30-day (odds ratio [OR], 0.72; P=0.004), 1-year (OR, 0.83; P=0.01) and 2-year (OR, 0.86; P=0.02), but not at long-term follow-up (rate ratio [RR], 1.02 [CI, 0.92 to 1.13]; P=0.67).
Source: The American Journal of Cardiology - November 6, 2019 Category: Cardiology Authors: Xinlin Zhang, Tingyu Wang, Rongfang Lan, Qing Dai, Lina Kang, Lian Wang, Yong Wang, Wei Xu, Biao Xu Source Type: research
